Related Experiment Videos
The effect in the KHT sarcoma of CCNU and MISO on cell cycle progression evaluated by flow-cytometry
Abstract:
Previous studies using the KHT sarcoma have shown that misonidazole (MISO) enhances the cytotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) by as much as a factor of 2.0. In the present study flow cytometry was used to monitor the changing DNA distributions of cells dissociated from solid tumors at successive times following treatment with CCNU, applied either alone or in combination with 0.5 mg/g MISO. The proportion of cells in late S and the G2M phases of the cell cycle increased gradually after CCNU treatment. MISO did not significantly change this block in cell progression, which persisted for at least 48 hr after treatment in all cases. CCNU shows marked carbamoylating activity, which has been associated with inhibition of RNA processing and with the degree of chemopotentiation achieved with MISO. Consequently, to evaluate whether MISO chemopotentiation was influencing the RNA distributions in tumors, RNA histograms were generated using acridine orange to differentially stain cellular DNA and RNA. By 24 hr after treatment, CCNU clearly altered the distribution of RNA, but no significant differences could be detected between results obtained from drug and drug plus sensitizer treated groups. These studies demonstrate the effect of CCNU on cell cycle progression in vivo. The addition of MISO did not result in further perturbation of the total tumor population, suggesting that cell cycle redistribution does not play a major role in chemopotentiation by MISO.
Insights
Misonidazole (MISO) enhances chemotherapy drug 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) efficacy, but does not alter its cell cycle effects. MISO did not further perturb the tumor cell population after CCNU treatment.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- Misonidazole (MISO) is known to enhance the cytotoxic effects of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).
- CCNU exhibits significant carbamoylating activity, potentially affecting RNA processing and contributing to MISO's chemopotentiation.
- Understanding the impact of MISO and CCNU on tumor cell cycle dynamics is crucial for optimizing cancer therapy.
Purpose of the Study:
- To investigate the effects of CCNU, alone and with MISO, on DNA distribution and cell cycle progression in KHT sarcoma tumors.
- To determine if MISO chemopotentiation influences RNA distribution within tumor cells following CCNU treatment.
Main Methods:
- Flow cytometry was employed to analyze DNA distributions of tumor cells at various time points post-treatment.
- RNA histograms were generated using acridine orange staining to assess cellular RNA content.
- Tumors were treated with CCNU alone or in combination with MISO.
Main Results:
- CCNU treatment led to a gradual increase in cells within the late S and G2M phases of the cell cycle.
- This cell cycle block persisted for at least 48 hours, and MISO did not significantly alter this progression.
- CCNU altered RNA distribution by 24 hours, but MISO did not cause further significant changes compared to CCNU alone.
Conclusions:
- CCNU significantly impacts cell cycle progression in vivo.
- MISO's chemopotentiation of CCNU does not appear to be mediated by further perturbation of the overall tumor cell population or cell cycle redistribution.